Company intelligence / Profile preview
ProbioTech
United Statesprobiotechusa.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Clinical evidence supports efficacy in improving gut/vaginal/immune/skin health using patented dual-phase delivery of probiotics/prebiotics plus antioxidants. Products are currently available OTC with plans to enter the prescription market targeting acute/chronic diseases such as C. difficile infection and ulcerative colitis.
- Therapeutic areas
- OncologyImmunologyOtherDermatologyNeurologyGastroenterologyNephrologyInfectious Diseases
- Modalities
- Live biotherapeutic product therapyProbiotic therapyPrebiotic therapyAntioxidant-based therapy
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on ProbioTech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ProbioTech.